Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
AIM
$1.07
$
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. The company is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
Next Earnings
2026-02-25
Beta
1.237
Average Volume
Market Cap
Last Dividend
CIK
0000946644
ISIN
US00901B3033
CUSIP
00901B105
CEO
Thomas K. Equels
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
21
IPO Date
1995-11-02
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca's Durvalumab in the Treatment of Metastatic Pancreatic Cancer | OCALA, Fla., Feb. 23, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced milestones in the expected timeline for the ongoing Phase 2 clinical study evaluating AIM's drug Ampligen® (rintatolimod) combined with AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) in the treatment of metastatic pancreatic cancer patients with stable disease post-FOLFIRINOX standard of care (the “DURIPANC” study) (see: ClinicalTrials.gov NCT05927142). | GlobeNewsWire | 2026-02-23 08:55:00 |
| TomCo Energy agrees new Valkor deal and raises some working capital, shares drop | TomCo Energy PLC (AIM:TOM, OTC:TMCGF) shares dropped 35% on Monday, falling to 0.035p, impacted by expected new equity dilution, after it announced a renewed partnership with Valkor LLC that leaves the pair jointly controlling Greenfield Energy on a 50:50 basis, as the AIM-listed group looks to progress oil-sands opportunities in Utah's Uinta Basin. The reset comes with balance-sheet engineering. | Proactive Investors | 2026-02-23 05:06:04 |
| Rome Resources unearths "exciting new areas" for tin and copper at Mont Agoma | Rome Resources Plc (AIM:RMR, FRA:33R) has sharpened drill targeting at its Mont Agoma prospect in the Democratic Republic of Congo after a new geological interpretation outlined fresh, high-priority zones for both tin and copper beyond the current footprint. The AIM-listed explorer said specialist consultancy Chemostrat reworked its geological and assay database and identified a marker horizon above “Zone 3” that better predicts where mineralisation sits, splitting the sequence into five zones. | Proactive Investors | 2026-02-19 03:28:56 |
| Seeing Machines flags second-half profit as EU car safety deadline nears | Seeing Machines Ltd (AIM:SEE, OTC:SEEMF, FRA:M2Z), the AIM-listed computer vision technology company, said it expected automotive production volumes to “increase materially” in the coming quarters as the EU's General Safety Regulation deadline approaches. In the update, it also forecast positive adjusted earnings before interest, tax, depreciation and amortisation in the third quarter and the second half of its financial year. | Proactive Investors | 2026-02-18 02:51:29 |
| Falcon Oil & Gas Ltd. - Notice of Cancellation of Admission to Trading on AIM | Falcon Oil & Gas Ltd. (“Falcon”) Notice of Cancellation of Admission to Trading on AIM 17 February 2026 - Falcon Oil & Gas Ltd. | GlobeNewsWire | 2026-02-17 02:00:00 |
| CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering | This press release is issued solely to correct a date from an AIM press release dated February 11, 2026. The Subscription Rights will expire if they are not exercised by 5:00 p.m., Eastern Time, on February 27, 2026, the expected expiration date of the Rights Offering. | GlobeNewsWire | 2026-02-12 16:35:00 |
| AIM ImmunoTech Announces Commencement of Rights Offering | OCALA, Fla., Feb. 11, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – today announced that it has commenced its previously disclosed rights offering (the “Rights Offering”). | GlobeNewsWire | 2026-02-11 08:30:00 |
| Aimia Inc. (AIM:CA) M&A Call Transcript | Aimia Inc. (AIM:CA) M&A Call Transcript | Seeking Alpha | 2026-02-09 12:14:19 |
| Cora Gold shares fall 12% after it unveils fundraiser for Mali project | Shares in West African explorer Cora Gold Ltd (AIM:CORA, FRA:C0J) dropped sharply after the company secured up to £15.7 million in new funding to advance its flagship mine in Mali towards production. Cora, which trades on London's AIM market, announced it had raised a minimum of £12.9 million and up to £13.7 million through a subscription led by Singapore-based investor Eagle Eye Asset Holdings. | Proactive Investors | 2026-02-09 04:22:18 |
| AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial | Live video webcast on Wednesday, February 11 th at 1:40 PM EST | GlobeNewsWire | 2026-02-06 08:55:00 |
| AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer | Year-end report discusses combination therapy's Mechanism of Action activating both innate and adaptive immune responses Year-end report discusses combination therapy's Mechanism of Action activating both innate and adaptive immune responses | GlobeNewsWire | 2026-02-05 08:40:00 |
| GlobalData shares rise as firm confirms move to London Main Market | Industry intelligence provider to delist from AIM in March and join Official List via introduction GlobalData PLC (AIM:DATA) shares rose 2% to 97.2p after the company confirmed plans to transfer its listing from AIM to the London Stock Exchange's Main Market on 5 March 2026. The information services group said it will apply for admission of its entire issued ordinary share capital to the Equity Shares (Commercial Companies) segment of the Financial Conduct Authority's Official List. | Proactive Investors | 2026-02-04 03:32:58 |
| Are Medical Stocks Lagging AIM ImmunoTech (AIM) This Year? | Here is how AIM ImmunoTech Inc. (AIM) and Cullinan Therapeutics (CGEM) have performed compared to their sector so far this year. | Zacks Investment Research | 2026-01-28 10:41:32 |
| AIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights Offering | OCALA, Fla., Jan. 23, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, announced today an informational update to its security holders regarding its proposed rights offering (the “Rights Offering”) and the expected key dates and terms relative to the Rights Offering. Assuming that the Rights Offering is fully subscribed, the Company will receive gross proceeds of $12 million, less expenses related to the Rights Offering. | GlobeNewsWire | 2026-01-23 13:22:00 |
| KEFI edges higher on Saudi minerals tie-up hopes | Shares in KEFI Gold and Copper PLC (AIM:KEFI, OTC:KFFLF, FRA:KMSA) rose 7% to 1.42p on Friday after the company responded to speculation around a possible new joint venture in Saudi Arabia. The AIM-quoted precious metals group, which is in the mine construction phase in Ethiopia, said its Saudi Gold and Minerals SLA (known as GMCO), in which it holds a 13% stake, is working with local conglomerate AJ Lan Group on a potential deal. | Proactive Investors | 2026-01-23 07:13:13 |
| Aimia (TSE:AIM) Shares Pass Above Two Hundred Day Moving Average – Here’s Why | Aimia Inc. (TSE: AIM - Get Free Report)'s share price crossed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of C$2.97 and traded as high as C$3.04. Aimia shares last traded at C$3.03, with a volume of 26,135 shares traded. Aimia Stock Down 0.3% The business has | Defense World | 2026-01-21 03:46:53 |
| Artemis Resources drops as it heads for AIM exit | Artemis Resources Ltd (ASX:ARV, AIM:ARV, OTCQB:ARTTF, FRA:ATY) shares dropped around 20% on Thursday after it announced the cancellation of its AIM market admission, effective from 13 February 2026. The decision follows a review of the costs and benefits of maintaining the dual listing. | Proactive Investors | 2026-01-15 04:59:53 |
| Is AIM ImmunoTech (AIM) Stock Outpacing Its Medical Peers This Year? | Here is how AIM ImmunoTech Inc. (AIM) and Alzamend Neuro, Inc. (ALZN) have performed compared to their sector so far this year. | Zacks Investment Research | 2026-01-08 10:41:03 |
| Directa Plus shares slide 23% as cash falls and funding needs loom | Shares in Directa Plus PLC (AIM:DCTA, OTC:DTPKF) fell 23% to 10.44p after the AIM-listed graphene specialist flagged a sharp drop in cash and warned that fresh funding will be needed to support growth in 2026. The company said it expects full-year revenues of €7.0 million, up modestly from €6.66 million last year, with an adjusted loss before interest, tax, depreciation and amortisation of about €2.5 million. | Proactive Investors | 2026-01-07 04:03:38 |
| Massimo Group to Exhibit at AIM Expo 2026, Showcasing New Sentinel UTV and MVR HVAC Pro Series Platforms | GARLAND, Texas, Jan. 6, 2026 /PRNewswire/ -- Massimo Group (NASDAQ: MAMO), a manufacturer and distributor of powersports vehicles and electric utility products, today announced it will exhibit at AIM Expo, North America's premier powersports industry event, taking place in Anaheim, California January 7-9, 2026. The Company will showcase its new 2026 product lineup and engage with both existing and prospective dealer partners. | PRNewsWire | 2026-01-06 08:00:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 424B4 | 2026-02-17 | 2026-02-17 | View Filing |
| EFFECT | 2026-02-10 | 2026-02-11 | View Filing |
| S-1/A | 2026-02-10 | 2026-02-10 | View Filing |
| 4 | 2026-02-06 | 2026-02-06 | View Filing |
| 8-K | 2026-02-05 | 2026-02-05 | View Filing |
| S-1/A | 2026-01-29 | 2026-01-29 | View Filing |
| S-1/A | 2026-01-23 | 2026-01-23 | View Filing |
| 8-K | 2026-01-20 | 2026-01-20 | View Filing |
| 8-K | 2026-01-12 | 2026-01-12 | View Filing |
| 8-K | 2025-12-17 | 2025-12-17 | View Filing |
| S-1 | 2025-12-12 | 2025-12-11 | View Filing |
| 8-K | 2025-11-19 | 2025-11-19 | View Filing |
| 10-Q | 2025-11-17 | 2025-11-17 | View Filing |
| NT 10-Q | 2025-11-17 | 2025-11-17 | View Filing |
| 424B5 | 2025-10-30 | 2025-10-30 | View Filing |
| 8-K | 2025-10-29 | 2025-10-29 | View Filing |
| DEF 14A | 2025-10-29 | 2025-10-29 | View Filing |
| 10-Q | 2025-08-14 | 2025-08-14 | View Filing |
| 8-K | 2025-07-31 | 2025-07-31 | View Filing |
| 424B5 | 2025-07-30 | 2025-07-30 | View Filing |
| EFFECT | 2025-07-29 | 2025-07-29 | View Filing |
| 8-K | 2025-07-28 | 2025-07-28 | View Filing |
| S-1/A | 2025-07-22 | 2025-07-22 | View Filing |
| 4 | 2025-07-21 | 2025-07-21 | View Filing |
| S-8 | 2025-07-15 | 2025-07-15 | View Filing |
| S-1/A | 2025-07-15 | 2025-07-15 | View Filing |
| EFFECT | 2025-07-07 | 2025-07-07 | View Filing |
| S-3/A | 2025-06-27 | 2025-06-27 | View Filing |
| 8-K | 2025-06-20 | 2025-06-20 | View Filing |
| 4 | 2025-06-16 | 2025-06-16 | View Filing |
| 4 | 2025-06-13 | 2025-06-13 | View Filing |
| 8-K | 2025-06-12 | 2025-06-12 | View Filing |
| 10-Q | 2025-05-15 | 2025-05-15 | View Filing |
| 8-K | 2025-05-01 | 2025-04-30 | View Filing |
| 4 | 2025-04-23 | 2025-04-23 | View Filing |
| 4 | 2025-04-23 | 2025-04-23 | View Filing |
| 4 | 2025-04-23 | 2025-04-23 | View Filing |
| 4 | 2025-04-07 | 2025-04-07 | View Filing |
| 8-K | 2025-04-07 | 2025-04-04 | View Filing |
| 4 | 2025-04-04 | 2025-04-04 | View Filing |
| 8-K | 2025-04-04 | 2025-04-04 | View Filing |
| DEF 14A | 2025-04-02 | 2025-04-02 | View Filing |
| S-3 | 2025-04-01 | 2025-04-01 | View Filing |
| 10-K | 2025-03-27 | 2025-03-27 | View Filing |
| 4 | 2025-03-18 | 2025-03-18 | View Filing |
| 4 | 2025-03-18 | 2025-03-18 | View Filing |
| 4 | 2025-03-18 | 2025-03-18 | View Filing |
| 4 | 2025-03-06 | 2025-03-06 | View Filing |
| 4 | 2025-03-05 | 2025-03-05 | View Filing |
| 4 | 2025-03-04 | 2025-03-04 | View Filing |
| 4 | 2025-03-04 | 2025-03-04 | View Filing |
| 4 | 2025-03-04 | 2025-03-04 | View Filing |
| 4 | 2025-03-04 | 2025-03-04 | View Filing |
| PRE 14A | 2025-02-28 | 2025-02-28 | View Filing |
| 8-K | 2025-02-28 | 2025-02-28 | View Filing |
| 3 | 2025-02-26 | 2025-02-26 | View Filing |
| 8-K | 2025-02-26 | 2025-02-26 | View Filing |
| 4/A | 2025-02-20 | 2025-02-20 | View Filing |
| 4/A | 2025-02-20 | 2025-02-20 | View Filing |
| 4/A | 2025-02-20 | 2025-02-20 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| 4 | 2025-02-19 | 2025-02-19 | View Filing |
| SC 13G/A | 2025-02-14 | 2025-02-14 | View Filing |
| 8-K | 2025-02-11 | 2025-02-11 | View Filing |
| 8-K | 2025-02-11 | 2025-02-11 | View Filing |
| S-1/A | 2025-02-07 | 2025-02-07 | View Filing |
| 8-K | 2025-02-07 | 2025-02-07 | View Filing |
| 8-K | 2025-02-05 | 2025-02-05 | View Filing |
| 4 | 2025-02-03 | 2025-02-03 | View Filing |
| 4 | 2025-02-03 | 2025-02-03 | View Filing |
| S-1/A | 2025-02-03 | 2025-02-03 | View Filing |
| S-1 | 2025-01-23 | 2025-01-23 | View Filing |
| 4 | 2025-01-21 | 2025-01-21 | View Filing |
| 4 | 2025-01-17 | 2025-01-17 | View Filing |
| 4 | 2025-01-17 | 2025-01-17 | View Filing |
| 4 | 2025-01-03 | 2025-01-03 | View Filing |
| 4 | 2025-01-03 | 2025-01-03 | View Filing |
| 4 | 2025-01-03 | 2025-01-03 | View Filing |
| 8-K | 2024-12-23 | 2024-12-23 | View Filing |
| 3 | 2024-12-23 | 2024-12-23 | View Filing |
| SC 13D/A | 2024-12-23 | 2024-12-23 | View Filing |
| 8-K | 2024-12-20 | 2024-12-20 | View Filing |
| 4 | 2024-12-20 | 2024-12-20 | View Filing |
| 4 | 2024-12-19 | 2024-12-19 | View Filing |
| 8-K | 2024-12-17 | 2024-12-17 | View Filing |
| 4 | 2024-12-17 | 2024-12-17 | View Filing |
| 4 | 2024-12-17 | 2024-12-17 | View Filing |
| 4 | 2024-12-17 | 2024-12-17 | View Filing |
| DEFA14A | 2024-12-17 | 2024-12-17 | View Filing |
| SC 13D/A | 2024-12-17 | 2024-12-17 | View Filing |
| DFAN14A | 2024-12-16 | 2024-12-16 | View Filing |
| DEFA14A | 2024-12-16 | 2024-12-16 | View Filing |
| DFAN14A | 2024-12-13 | 2024-12-13 | View Filing |
| DEFA14A | 2024-12-12 | 2024-12-12 | View Filing |
| DFAN14A | 2024-12-12 | 2024-12-12 | View Filing |
| DFAN14A | 2024-12-12 | 2024-12-12 | View Filing |
| DFAN14A | 2024-12-11 | 2024-12-11 | View Filing |
| DEFA14A | 2024-12-10 | 2024-12-10 | View Filing |
| DFAN14A | 2024-12-10 | 2024-12-10 | View Filing |
| DFAN14A | 2024-12-10 | 2024-12-10 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|